Lee Ainslie - Maverick Capital
Holding/activity history for Alnylam Pharmaceuticals, Inc. (ALNY)
← All ALNY superinvestors
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2021 Q4 | 0 | 0.00 | Sell 100.00% | <0.01 | $154.82–212.00 · VW $177.06i | SEC | |
| 2021 Q3 | 3,983 | <0.01 | Reduce 98.64% | 0.46 | $166.16–209.73 · VW $187.65i | $752,000 | SEC |
| 2021 Q2 | 292,683 | 0.47 | Reduce 63.24% | 0.65 | $125.08–177.53 · VW $150.11i | $49,616,000 | SEC |
| 2021 Q1 | 796,234 | 1.03 | Reduce 19.12% | 0.39 | $124.00–178.41 · VW $149.38i | $112,420,000 | SEC |
| 2020 Q4 | 984,502 | 2.05 | Add 1.76% | 0.04 | $119.29–148.76 · VW $131.28i | $127,956,000 | SEC |
| 2020 Q3 | 967,461 | 2.62 | Reduce 13.12% | 0.46 | $119.67–167.33 · VW $143.65i | $140,862,000 | SEC |
| 2020 Q2 | 1,113,608 | 3.47 | Reduce 16.88% | 0.52 | $98.01–158.37 · VW $135.60i | $164,936,000 | SEC |
| 2020 Q1 | 1,339,705 | 3.08 | Reduce 40.74% | 1.54 | $84.97–134.51 · VW $114.22i | $145,827,000 | SEC |
| 2019 Q4 | 2,260,897 | 3.79 | Reduce 29.85% | 1.14 | $73.32–125.72 · VW $103.48i | $260,388,000 | SEC |
| 2019 Q3 | 3,222,813 | 3.81 | Reduce 23.92% | 1.07 | $69.11–88.00 · VW $78.51i | $259,179,000 | SEC |
| 2019 Q2 | 4,236,016 | 4.46 | Add 31.95% | 1.08 | $65.81–96.08 · VW $77.63i | $307,365,000 | SEC |
| 2019 Q1 | 3,210,387 | 4.09 | Add 14.50% | 0.52 | $70.29–93.95 · VW $84.14i | $300,011,000 | SEC |
| 2018 Q4 | 2,803,951 | 3.07 | Add 85.44% | 1.41 | $60.27–90.00 · VW $77.35i | $204,436,000 | SEC |
| 2018 Q3 | 1,512,064 | 1.71 | Add 121.92% | 0.94 | $86.95–124.22 · VW $105.07i | $132,336,000 | SEC |
| 2018 Q2 | 681,354 | 0.81 | Buy | 0.81 | $87.35–118.71 · VW $100.34i | $67,107,000 | SEC |
Price snapshot:
Current price$288.06
52-week low$273.11
52-week high$495.55